[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100568655":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":22,"locations":10,"responsibleParty":28,"collaborators":10,"id":30,"slug":31,"hasResults":32,"nctId":33,"briefTitle":34,"officialTitle":35,"acronym":36,"eligibilityCriteria":37,"healthyVolunteers":38,"sex":39,"minAge":40,"maxAge":41,"enrollmentInfo":42,"targetDuration":10,"studyType":45,"phases":10,"briefSummary":46,"conditions":47,"keywords":51,"overallStatus":55,"whyStopped":10,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":10},{"fullName":5,"class":6},"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"NAC group",null,"Participants will receive 6 cycles of TEC\u002FTAC neoadjuvant chemotherapy, and radical mastectomy after chemotherapy. Clinicopathological data, chemotherapy-related adverse events and prognostic information of patients should be collected during the study. 5ml peripheral venous blood will be collected before chemotherapy, after 2 cycles of chemotherapy, before surgery, and six months after surgery.",[13],"Drug: docetaxel, anthracycline, cyclophosphamide",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","docetaxel, anthracycline, cyclophosphamide","1. Participants were required to receive 6 cycles of TEC\u002FTAC neoadjuvant chemotherapy, and radical mastectomy was required after chemotherapy.\n2. 5ml peripheral venous blood was collected before chemotherapy, after 2 cycles of chemotherapy, before surgery, and six months after surgery.\n3. Clinicopathological data, chemotherapy-related adverse events and prognostic information of patients should be collected during the study.",[9],[21],"G-CSF",[23],{"name":24,"role":25,"phone":26,"phoneExt":10,"email":27},"Wang","CONTACT","0086-15850582852","njmuwangwei@163.com",{"type":29,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100568655","studying-the-senescent-t-cell-features-and-its-relationship-with-the-chemotherapy-efficacy-in-young-tnbc-100568655",false,"NCT06684054","Studying the Senescent T Cell Features and Its Relationship with the Chemotherapy Efficacy in Young TNBC","Study of the Features of Senescent T Lymphocytes Induced by Chemotherapy and Its Relationship with the Efficacy of Neoadjuvant Chemotherapy in Young Triple-negative Breast Cancer Patients, a Single-center, Observational Study.","STFREiYTNBC","Inclusion Criteria:\n\n1. Female, age≤40 years old,\n2. Invasive breast cancer confirmed by pathology, immunohistochemistry showed TNBC (ER-, PR-, HER2-),\n3. Indications for neoadjuvant chemotherapy according to guidelines: tumor diameter \\> 2cm or with axillary lymph node metastasis or desiring breast-conserving surgery but should obtain negative surgical margins through neoadjuvant chemotherapy.\n\nExclusion Criteria:\n\n1. Stage IV patients or a history of other malignancies,\n2. Having microbial infection or autoimmune disease have not been cured or having HBV, HIV infection,\n3. Having surgery 3 months before enrollment,\n4. Patients with insufficient clinicopathological data,\n5. Does not meet the indications for neoadjuvant chemotherapy or is unwilling to cooperate.",true,"FEMALE","18 Years","40 Years",{"count":43,"type":44},30,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to learn about the features of senescent T lymphocytes induced by chemotherapy and its relationship with the efficacy of neoadjuvant chemotherapy in young triple-negative breast cancer (TNBC) patients.\n\nThe main questions it aims to answer are:\n\n* What are the senescent features of peripheral T lymphocytes in young TNBC patients receiving neoadjuvant chemotherapy and the relationship with the efficacy of neoadjuvant chemotherapy?\n* What is the relationship between senescent T cells and adverse events, DFS and tumor infiltrating lymphocytes?\n\n  1. Participants will receive 6 cycles of docetaxel + adriamycin\u002Fepirubicin + cyclophosphamide (TEC\u002FTAC) neoadjuvant chemotherapy, and radical mastectomy after chemotherapy.\n\n2.5ml peripheral venous blood will be collected before chemotherapy, after 2 cycles of chemotherapy, before surgery, and six months after surgery.\n\n3.Clinicopathological data, chemotherapy-related adverse events and prognostic information of patients should be collected during the study.",[48,49,50],"T-Cell Dysfunction","Chemotherapy Effect","Adverse Events",[52,53,54],"breast cancer","senescence","chemotherapy","NOT_YET_RECRUITING","2024-11-10",{"date":58,"type":59},"2024-11-12","ACTUAL",{"date":61,"type":44},"2025-01-01",{"date":63,"type":44},"2027-12-31",{"name":5,"class":6}]